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Ovarian cancer marker CA 125 was measured in human
seminal plasma, and the concentrations ranged between 22
and 1149 U/ml, and between 39 and 4711 U/ejaculate. This
very high patient-to-patient variability was in contrast
to a much lower within-patient variability, which was
comparable to that of other semen parameters. No signific-
ant differences in CA 125 concentration were found in
seminal plasma from normospermic patients, patients with
male factors, vasectomized men, and in aliquots of samples
which led to a pregnancy, via artificial insemination or
in-vitro fertilization. The seminal plasma CA 125 concen-
tration was not correlated with sperm count, motility
and morphology. In contrast, seminal plasma CA 125
concentrations correlated with the age of the patient (P <
0.001) and inversely with the volume of the ejaculate (P <
0.001). These correlations were independent of each other.
CA 125 did not correlate with the prostatic marker zinc,
but did do so with the seminal vesicle marker fructose and
the epididymal marker carnitine.
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Introduction
Cancer antigen 125 (CA 125) was discovered by Bast et al.
in 1981, by immunizing mice against an ovarian carcinoma cell
line. The monoclonal antibody obtained, OC 125, recognized an
antigenic determinant present on a high molecular weight
glycoprotein, CA 125. The precise biochemical structure of
CA 125 is still unknown.
CA 125 is a tumour marker widely used for monitoring
ovarian cancer (see Jacobs and Bast, 1989, for review). Beside
ovarian cancers, circulating concentrations of CA 125 are
elevated in various pathological and physiological conditions
such as endometriosis (Giudice et al, 1986; Fedele et al,
1988; Muyldermans et al, 1995), pelvic inflammatory disease
(Takahashi et al, 1990), endometrial cancer (Duk et al., 1986),
early pregnancy (Haga et al., 1986) and during menses
(Pittaway and Fayez, 1987).
ImmunohistochemicaLly, CA 125 is localized on covering
epithelia, such as peritoneum, pleura, pericardium, endo-
metrium and Fallopian tube. It probably undergoes exocrine
secretion into the body's cavities (see Bischof, 1993, for
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review). CA 125 is also present in uterine fluid (Weintraub
et al., 1990), cervical mucus (Crombach et al, 1989), human
milk (Hanisch et al, 1985), amniotic fluid (O'Brien et al,
1986), follicular fluid (Mordel et al, 1992) and seminal plasma
(Halila, 1985; Dodd et al., 1987; Matorras et al, 1994).
In this study we measured CA 125 in human seminal
plasma and studied the possible correlation between CA 125
concentrations and semen parameters.
Materials and methods
Study I
Semen samples (n = 163) were obtained from 126 patients (ages
ranged from 26 to 64 years) attending the infertility clinic for in-vitro
fertilization (TVF, n = 97), gamete intra-Fallopian transfer (GIFT,
n = 1), artificial insemination with the husband's spermatozoa (AM,
n = 50) or sperm preparation tests (n = 15).
The original sperm parameters (volume, sperm concentration, initial
motility, morphology) were recorded and then the samples were
processed for sperm preparation as follows. After adding 1-3 vol
of culture medium (Menezo's B2 from BioMerieux, Geneva,
Switzerland, or Whittingham's T6, prepared in our laboratory, with
or without 10% patient's own serum), the sample was centrifuged
and the supernatant harvested and stored frozen at -20°C. Record
was kept of the dilution factor. The pellet was then resuspended and
processed as required for sperm preparation.
CA 125 was measured in the supernatant with a commercially
available immunoradiometric assay (Centocor CA 125 TM; Medipro
AG, Teufen, Switzerland) and the initial concentration was calculated
taking into account the dilution ratio. All samples were analysed in
duplicates.
Samples were classified as normospermic if the sperm concentration
was >20xl06/ml, and there was 2*40% motility and s»30% normal
morphology. Samples not meeting these criteria were considered to
have male factor infertility.
For the semen used for ATH, IVF and GIFT, the pregnancies
obtained were noted and, for the FVF patients, the fertilization rate
was calculated and recorded.
Study II
Semen samples (n = 39) were obtained from patients coming for a
semen analysis to the andrology laboratory. After centrifugation, the
undiluted seminal plasma was tested for fructose, zinc, carnitine and
CA 125.
CA 125 was measured with a commercially available immuno-
radiometric assay, ELSA-CA 125 II (CIS, Gif-sur-Yvette, France),
which we ascertained gave very similar results to the Centocor CA
125 assay (Clement et al., 1995).
Fructose concentrations were measured with the commercial
Enzymatic Bioanalysis Kit from Boehringer Mannheim (Rotkreuz,
Switzerland), and the results expressed in umol/ejaculate. Zinc
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Table I. Distribution parameters of the variables used in the study
CA 125 (U/ml)
Variable Skewness Kurtosis
CA 125 (U/ml)
Log CA 125 (U/ml)*
CA 125 (U/ejaculate)
LogCA 125 (U/ejaculate)*
Ejaculate volume (ml)
Log ejaculate volume (ml)*
Age of the male (years)
Log age of the male (years)*
Fructose (jimol/ejaculate)*
Log fructose (umol/ejaculate)
Zinc (umol/ejaculate)
Log zinc (jimol/ejaculate)1
Camitine (umol/ejaculate)
Log camitine (jimol/ejaculate)*
1.646
0.05
3.336
0.008
1.522
-0.279
1.025
0.448
0.015
5.075
1.97
0.402
1.243
0.176
2.533
-0.78
13.536
0.145
3.393
0.688
1.45
0.211
-0.716
-2.013
3.386
0.152
0.913
-0.82
•Parameters used for statistical evaluation.
Table n . Patient-to-patient and within-patient variation coefficients (%) for
seminal plasma CA 125 concentrations and other semen parameters
Variable Patient-to-patient
variation (n = 98)
Within-patient
variation (n = 28)
CA 125 (U/ml)
CA 125 (U/ejaculate)
Ejaculate volume (ml)
Sperm count (XlO'/ml)
Moulity (%)
84.3
107.3
50.5
103.2
44.5
28.4
26.5
23.4
40.9
24.6
(Fuentes et al., 1982) and camitine (Wettcraucr and Heitc, 1976)
were also measured and the results expressed in (imol/ejaculate.
Statistics
Logarithmic transformations were used throughout the study for the
parameters which showed a skewed distribution (Table I). Student's
/-test and correlation coefficient r were thus calculated on log-
transformed data when appropriate.
Results
Study I
To ensure that dilution by culture medium had no effect on
CA 125 measurements, six samples were measured diluted and
undiluted. After multiplying the diluted CA 125 values by the
dilution ratio, a correlation of 0.945 was obtained between the
values (results not shown). No differences were observed
between the two media used to dilute the samples (B2 and T6),
and the presence of 10% serum had no effect either. Furthermore,
CA 125 was undetectable in any of the media used.
CA 125 was measurable in the 163 seminal plasma samples
tested and the concentrations ranged from 22 to 1149 U/ml and
from 39 to 4711 U/ejaculate.
The patient-to-patient variability coefficient of CA 125 was
very high (84-107%, Table II). As 28 patients gave more than
one semen sample (between two and five samples/patient), a
within-patient variability coefficient (mean of the variability
coefficients for each patient) could be calculated (Table II).
Within-patient variability was much lower (26-28%) and was
Normoapermic*
(n = 40)
Male factors -
(n = 102)
Fertilization
(n = 74)
No fertilization -
(n = 23)
Pregnancies -(n=14)
Vasectomized
(n = 5)
Figure 1. Distribution of CA 125 concentrations in seminal
plasma of nonnospermic men, patients with male factors, patients
whose spermatozoa fertilized in IVF and patients whose
spermatozoa did not, patients who obtained a pregnancy (by
in-vitro fertilization or artificial insemination with husband's
spermatozoa) and vasectomized men. Medians are indicated by a
horizontal bar.
not different from that of other semen parameters (volume,
concentration and motility).
As shown in Figure 1, CA 125 concentrations in seminal
plasma from normospermic men, from patients with male fac-
tors, from semen samples which were able or unable to fertilize
in IVF, from semen leading to a pregnancy in AIH or IVF,
or from vasectomized men were all similar. Furthermore, no
correlation could be observed between CA 125 values and sperm
concentration, motility, or morphology (results not shown).
However, the CA 125 values in seminal plasma were positively
correlated with the age of the male patient (P < 0.001, Figure
2) but negatively with the volume of the ejaculate (P < 0.001,
Figure 3). The volume of the ejaculate was weakly negatively
correlated with the age of the patient, but not significantly so
(r = -0.14). Thus partial correlation coefficients were calculated
to evaluate the influence of age in the correlation C A 125/volume
and inversely the contribution of volume in the correlation CA
125/age. These partial correlation coefficients were slightly
lower, but still significant at P < 0.01.
Study II
CA 125 was measured in undiluted seminal plasma together
with fructose, zinc and camitine. These parameters ranged from
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r= 0.285, n = 148, P< 0.001
1.4 1.5 1.6 1.7 1.8
Log age of the male patients (y«ar»)
Figure 2. Correlation between seminal plasma CA 125 concentrations and the age of the patient.
1.9
-0.5 0.0 0.5
Log ejaculate volume (ml)
1.0
Figure 3. Correlation between seminal plasma CA 125 concentrations and the volume of the ejaculate.
4"
r< 0.489, no 39, P = 0.0016
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Fructose (jimol/e|aculate)
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Log Carnltlne (jimol/ejaculate)
Figure 4. Correlation between seminal plasma CA 125 and fructose (a) or camitine (b), expressed in units or |imol per ejaculate.
(1985) reported high concentrations of CA 125 in seminal
plasma, with a high patient-to-patient variability. He demon-
strated that seminal CA 125 reacted similarly to ovarian cancer
CA 125 in radioimmunoassay, and had a similar molecular
weight (130 kDa) on column chromatography. He could not
demonstrate any difference between CA 125 concentrations
of normospermic men, patients with suspected infertility and
those of vasectomized men, neither could he correlate seminal
plasma CA 125 concentrations with the patient's age or any
of the semen parameters tested (sperm count ejaculate volume
or motility). Dodd et at (1987) confirmed these results,
observing no relationship between CA 125 concentration and
85.8 to 1840.8 U/ejaculate forCA 125, from 1.36 to 201.3
ejaculate for fructose, from 2.85 to 39.5 |imol/ejaculate for zinc,
and from 0.3 to 3.92 (imol/ejaculate for camitine. There was no
significant correlation between concentration of CA 125 per
ejaculate and zinc (r = 0.081), but CA 125 concentration (U/
ejaculate) correlated significantly with fructose (P = 0.0016,
Figure 4a) and camitine (P = 0.03, Figure 4b).
Discussion
Although the presence of CA 125 in semen is well known,
there have been few reports published on the subject Halila
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number of spermatozoa, motility, vitality, morphology, or the
presence of round cells in the semen. In contrast, Matorras
et al. (1994) reported a tendency to higher CA 125 values in
pathological or borderline semen, and in patients who did not
obtain pregnancy.
In our study, the high patient-to-patient variability of the
concentrations of seminal plasma CA 125 was confirmed, the
values ranging from 22 to >1000 U/ml. On the other hand,
the variability of CA 125 values in different samples from the
same patient was much lower, and varied to the same extent
as other semen parameters (motility, sperm count and ejacu-
late volume).
We confirmed the results of Halila (1985) that there is no
difference in the CA 125 concentrations in samples from
normospermic men, patients with male factors or vasectomized
men. Furthermore, CA 125 values in seminal plasma were not
different between samples failing to fertilize in IVF when
compared to samples able to do so. This observation is in
contrast to the results reported by Matorras et al. (1995), who
observed higher CA 125 values in only four samples with no
fertilization. This discrepancy is obviously due to the small
number of observations in that study. Finally, samples leading
to a pregnancy had similar concentrations of CA 125 to those
not achieving a pregnancy. This observation confirms previous
results (Matorras et al, 1995).
No correlation could be demonstrated between CA 125
values and sperm count, motility or morphology. However, in
contrast to the other studies, a correlation (as calculated with
the log-transformed values) between CA 125 values and the
age of the patient and an inverse correlation between CA 125
values and the volume of the ejaculate were observed. These
observations could not be explained by a decrease of the
ejaculate volume with age. However, a diluting effect of the
fluids secreted by the glands not producing CA 125 could
explain this inverse correlation between CA 125 and the
volume. There is no clear explanation for the significant
correlation between age and CA 125. These correlations may
have been revealed because the number of samples tested in
the present study was larger than in the studies in which
correlations were not observed.
The concentration of CA 125 in seminal plasma is in
most cases much higher than the circulating concentrations,
suggesting a local production and secretion. With the intention
of determining which organ of the male genital tract could
produce the CA 125, we measured this antigen in undiluted
samples together with fructose, zinc and camitine. Fructose is
a marker of seminal vesicles, camitine of epididymis and zinc
of prostatic function. CA 125 concentration did not correlate
with zinc, suggesting that prostate is probably not a source of
CA 125. Furthermore, the normal concentrations of CA 125
in seminal plasma of vasectomized men excluded a unique
testicular or epididymal source, although the correlation
between camitine and CA 125 would indicate an epididymal
origin for that glycoprotein. Finally, the strong correlation
between fructose and CA 125 concentrations suggests that this
antigen is produced by the seminal vesicles. Immunohisto-
chemically, Kabawat et al. (1983) have shown that neither
normal testis nor epididymis or prostate reacted with the
monoclonal antibody OC 125, the seminal vesicles having
apparently not been examined.
Recently, Ohmori et al. (1994) reported a patient with an
adenocarcinoma of the seminal vesicle, who presented with
high circulating concentrations of CA 125 that decreased after
surgery was first performed and then rose again as the disease
relapsed. Half of the tumour cells were immunohistochemically
positive for CA 125. In contrast, in prostatic cancer or in
benign prostatic hyperplasia, immunohistochemical studies
were unable to detect CA 125 (Alivizatos et al, 1992; Loy
et al, 1992). Finally, Kabawat et al (1983) reported no
immunoreactivity of OC 125 monoclonal antibody with the
following testis tumours: seminoma, embryonic carcinoma and
Ley dig cell tumour, and Costa et al. (1992) showed that
Sertoli-stromal cell tumours were not stained for CA 125.
Furthermore, Buamah et al. (1987) found no elevation of CA
125 in sera from a patient with a non-seminomatous cell
tumour of the testis. We would thus conclude that CA 125
seems to be produced mainly by seminal vesicles. Future
studies will indicate whether CA 125 could possibly be used
as a marker of this gland
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